IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

ScinoPharm and TaiGen sign API manufacturing deal

9:39 AM MDT | June 9, 2014 | Deepti Ramesh

ScinoPharm (Tainan, Taiwan), a company that develops and manufactures active pharmaceutical ingredients (APIs), says that it has signed a manufacturing contract with TaiGen Biotechnology (Taipei) for the clinical supply of the API for Burixafor, a new chemical entity discovered and developed by TaiGen. The API will be manufactured at ScinoPharm’s plant at Changshu, China. “Burixafor is a 100% in-house-developed product that can be used in the treatment of various intractable diseases. The cooperation between TaiGen and ScinoPharm will not only be a...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa